Veterinary Vaccines Market Analysis & Forecast: 2025-2032

Veterinary Vaccines Market Size and Forecast – 2025 to 2032

The Veterinary Vaccines Market is estimated to be valued at USD 10.46 Bn in 2025 and is expected to reach USD 17.70 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.

To learn more about this report, Download Free Sample

Key Takeaways

• Based on Technology, the Live Attenuated Vaccines segment leads the market holing an estimated share of 37.3% in 2025, favored for their strong, long-lasting immunity and cost-effective use in mass livestock vaccination.
• Based on Animal Type, the Livestock segment is projected to dominate with a share of 58.8% in 2025, driven by mass immunization to protect meat, dairy, and poultry productivity.
• Based on Route of Administration, the subcutaneous injection segment is expected to account for 43.7% share of the market in 2025, due to ease of administration.
• Based on Distribution Channel, the Private segment is projected to lead the market with the largest share in 2025, due to robust infrastructure, high pet ownership, and efficient, customer-focused service delivery.
• Based on Region, North America is expected to lead the market, holding a share of 40.1% in 2025. While, Asia Pacific is anticipated to be the fastest growing region.

Market Overview

The market is expected to witness positive growth over the forecast period. Increasing pet adoption worldwide and rising awareness about animal health is expected to drive the demand for veterinary vaccines. Growing expenditure on animal health and increasing incidence of zoonotic diseases is further expected to support the market growth. Various initiatives taken by market players and government organizations to provide veterinary healthcare is also projected to boost the sales of vaccines. Wide availability of effective vaccines against various infectious diseases of livestock and companion animals along with increasing demand for vaccine from emerging economies will provide opportunities for expansion of the veterinary vaccines market globally over the coming years.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Innovation & R&D in the Veterinary Vaccines Market

Advanced Vaccine Technologies

• Recombinant DNA Vaccines: These offer targeted protection with fewer side effects, ideal for both livestock and companion animals.
• DIVA Marker Vaccines: Allow differentiation between infected and vaccinated animals, aiding disease surveillance and trade compliance like Biolumpivaxin for Lumpy Skin Disease.
• Serum-Free Formulations: AIM Vaccine’s rabies shot eliminates serum risks, improving safety and scalability.

Delivery Innovations

• Oral Wildlife Vaccines: USDA’s bait-based rabies vaccines for raccoons and foxes reduce human-animal contact and simplify mass immunization.
• Needle-Free Injectors: Jet injectors and transdermal patches are being explored for stress-free administration, especially in pets.

AI & Genomics Integration

• Predictive Modeling: AI helps forecast outbreaks and design vaccines tailored to regional pathogen strains.
• Genomic Surveillance: Real-time sequencing enables faster updates to vaccine formulations and precision targeting.

Global Collaboration

• Public-Private Partnerships: Joint efforts between governments, pharma companies, and NGOs accelerate vaccine development and deployment.
• One Health Approach: Integrated strategies address animal, human, and environmental health — especially for zoonotic threats.

Segmental Insights

To learn more about this report, Download Free Sample

Veterinary Vaccines Market Insights, By Animal Type - Livestock Lead Is Driven by Mass Immunization to Protect Meat, Dairy, And Poultry Productivity

In terms of animal type, the livestock segment contributes the highest share of the veterinary vaccines market demand and is projected to hold 58.8% of the market share in 2025. Vaccines play a critical role in safeguarding productivity and profitability of the meat, dairy, and poultry industries by shielding animals from common illnesses. Mass vaccination is routinely employed to combat pathogens like foot-and-mouth disease virus, avian influenza virus, swine influenza virus that threaten livestock populations. Endemic infections can wipe out entire herds if left unchecked, highlighting the business imperatives for immunization. Farmers depend on steady vaccine supplies to protect their investment and meet the rising global demand for animal proteins. Regulatory support and manufacturing standards have further increased access and reliability of veterinary biologics for large-scale livestock farms. These factors together ensure the sustained importance of vaccines in commercial livestock production systems.

For instance, in September 2025, India launched its first indigenous vaccine against Infectious Bovine Rhinotracheitis (IBR), a major cattle disease affecting productivity. Developed by the National Dairy Development Board and ICAR-NIVEDI, the vaccine aims to curb economic losses in the dairy sector. This milestone strengthens India’s veterinary capabilities and supports livestock health nationwide.

Veterinary Vaccines Market Insights, By Technology - Live Attenuated Vaccines Growth Is Favored for Their Strong, Long-Lasting Immunity and Cost-Effective Use in Mass Livestock Vaccination

In terms of technology, the live attenuated vaccines segment is anticipated to hold 37.3% of the market share in 2025. Live attenuated vaccines mimic natural infection by using a weakened form of the disease-causing pathogen that cannot multiply in the body or cause disease. They trigger long-lasting immune response in animals by closely mimicking natural infection. As they are genetically similar to wild-type pathogens, they induce both cellular and humoral immunity which provides strong protection. Their ability to induce a self-limiting infection allows for durable immunological memory to develop. Unlike inactivated vaccines, they require only one or two doses to confer lifelong immunity making them very cost-effective. Being non-toxic yet highly immunogenic makes them well-suited for mass vaccination programs in livestock. Their ease of administration also supports large-scale usage. While they pose minimal health risks, necessary quality control and handling precautions are maintained to prevent reversion to virulence. Widespread usage of live attenuated vaccines for rabies, distemper and influenza reflects their acceptance as a reliable technology.

For instance, in May 2025, Bharat Biotech’s subsidiary, Biofabri, launched the world’s first DIVA marker vaccine for Lumpy Skin Disease in India. This innovative vaccine enables differentiation between infected and vaccinated animals, aiding disease control and surveillance. The breakthrough marks a significant advancement in veterinary science and supports India’s efforts to safeguard livestock health.

Veterinary Vaccines Market Insights, By Route of Administration - Subcutaneous Injection Is Demanding Due To Ease of Administration

In terms of route of administration, the subcutaneous injection segment is projected to hold 43.7% of the market share in 2025. Subcutaneous administration enables easy self-administration or assistance by a non-medical person. It causes minimal discomfort to animals as the thin layer of fat beneath the skin forms an absorption site for vaccines. The risk of accidental needle injuries is also reduced compared to intramuscular injections which require precision. Subcutaneous vaccines tend to have fewer local reactions and are more acceptable to pet owners. Advances in formulation technologies have enhanced stability of some vaccines when delivered via this route. It has emerged as a practical option for implementations such as core vaccinations in veterinary clinics or emergency disease outbreak operations that require mass administration. With training and suitable products, subcutaneous delivery offers convenience without compromising efficacy, factors that have increased its popularity among vaccine makers and end users.

For instance, in June 2025, Boehringer Ingelheim introduced VAXXITEK® HVT+IBD+ND, a groundbreaking 3-in-1 poultry vaccine in India. Designed to protect against Marek’s Disease, Infectious Bursal Disease, and Newcastle Disease, the vaccine simplifies immunization protocols and enhances flock health. This launch marks a significant advancement in poultry disease prevention and supports sustainable farming practices.

Veterinary Vaccines Market Insights, By Distribution Channel - Private Dominate Due To Robust Infrastructure, High Pet Ownership, and Efficient, Customer-Focused Service Delivery

In terms of distribution channel, the private segment is expected to contribute the highest share of the market in 2025. This dominance is largely attributed to the presence of well-established veterinary infrastructure, which supports efficient supply chains and specialized services. In these regions, high levels of pet ownership and a strong emphasis on livestock productivity drive demand for advanced veterinary solutions. Private channels are better equipped to meet these demands through tailored offerings, faster delivery, and superior customer engagement. Moreover, private distributors often collaborate closely with veterinary clinics, hospitals, and retail outlets, ensuring a more responsive and market-driven approach compared to public systems, which may be constrained by regulatory and budgetary limitations.

For instance, in August 2025, DavaIndia launched the #CareForAll campaign to shelter and vaccinate stray dogs across India, aiming to improve animal welfare and public health. The initiative includes free anti-rabies vaccinations and partnerships with NGOs for rescue and care. This nationwide effort reflects a growing commitment to responsible pet care and humane treatment of stray animals.

Regional Insights

To learn more about this report, Download Free Sample

North America Veterinary Vaccines Market Analysis & Trends

North America has established itself as the dominant regional market for veterinary vaccines and is expected to hold 40.1% of the market share in 2025. With a strong presence of leading vaccine manufacturers and high pet ownership rates, the U.S. and Canada account for the majority of sales. Regulatory approvals are well-established in the region, allowing for a steady pipeline of new product launches yearly. Additionally, North American veterinary practices have deeply ingrained vaccine administration protocols. Combined with large procurement budgets of major buyers like veterinary hospitals and purchase alliances, stable and sizable demand is assured for suppliers. Some key vaccine categories where the region leads include core diseases like rabies, as well as emerging niche segments pertaining to canine and feline therapeutic applications. Export activity from North American players also contributes to their regional supremacy.

For instance, in August 2025, the USDA’s Animal and Plant Health Inspection Service (APHIS) launched its 2025 Oral Rabies Vaccination (ORV) campaign across 13 U.S. states. Targeting raccoons, the initiative uses baited vaccines distributed by air and ground to prevent the spread of rabies into America’s heartland, reinforcing national efforts to protect wildlife and public health.

Asia Pacific Veterinary Vaccines Market Analysis & Trends

Among the fastest growing regional markets for veterinary vaccines is Asia Pacific. Rising pet ownership in China and India due to growing affluence as well as a cultural shift toward companion animals is fueling vaccine requirement. The massive scale and sheer number of livestock heads across Southeast Asian nations translates to huge volume potential as well. While regulatory structures and standards are still developing, regional vaccine manufacturing capacities are being established or expanded through partnerships and foreign direct investments. This allows for vaccines to be produced and priced more competitively versus imports. Local manufacturing also overcomes past constraints around reliable supply and cold chain management. Nations like Thailand and Indonesia have emerged as regional export hubs, where vaccines manufactured onshore are distributed farther afield within Asia Pacific and beyond. With continued economic expansion projected across multiple high-growth countries, the Asia Pacific region is viewed as prime for sustained double-digit percentage increases in veterinary vaccine consumption over the medium term.

For instance, in January 2025, Indonesia launched a nationwide livestock vaccination campaign to combat the spread of foot-and-mouth disease (FMD), which has affected thousands of animals. The initiative aims to protect cattle and buffalo populations, safeguard food supply chains, and support rural economies. Authorities are prioritizing high-risk areas to contain the outbreak and prevent further transmission.

Veterinary Vaccines Market Outlook Country-Wise

The U.S. Veterinary Vaccines Market Trends

The United States leads the veterinary vaccines market, backed by advanced veterinary infrastructure, widespread pet insurance coverage, and robust livestock vaccination programs. High pet ownership and commercial farming drive consistent demand for preventive care. Government support and innovation in animal health technologies further strengthen the country’s position as a global leader in veterinary biologics.

For instance, in September 2025, Elanco announced FDA approval for an updated label of Zenrelia (ilunocitinib) tablets, removing the “vaccine-induced disease” language. This change reflects improved clarity and confidence in the product’s safety profile for canine allergic dermatitis treatment. The revision supports veterinarians in prescribing Zenrelia with greater assurance and aligns with evolving regulatory standards.

China Veterinary Vaccines Market Trends

China is witnessing surging demand for veterinary vaccines market, driven by rapid expansion in livestock farming and heightened awareness of zoonotic diseases. As the country intensifies efforts to safeguard food security and public health, mass immunization programs and improved veterinary infrastructure are gaining momentum. These trends position China as a key player in the global animal health market.

For instance, in April 2025, China’s AIM Vaccine Co., Ltd. unveiled the world’s first serum-free rabies vaccine following regulatory approval. This breakthrough eliminates serum-related risks and enhances safety for both humans and animals. With market clearance and production underway, the innovation marks a significant advancement in global rabies prevention and vaccine technology.

Market Report Scope

Veterinary Vaccines Market Report Coverage

Veterinary Vaccines Market Driver

Increasing government initiatives for veterinary vaccine

The Veterinary Vaccines Market share is witnessing notable expansion, driven by a combination of rising awareness about animal health, increasing pet ownership, and the growing demand for livestock productivity. Governments across the globe are actively supporting vaccination programs to curb the spread of zoonotic diseases and ensure food security, which in turn is boosting the adoption of veterinary vaccines. These initiatives, coupled with technological advancements in vaccine development, such as DNA vaccines and recombinant vaccines are enabling manufacturers to capture larger portions of the market. Moreover, regions with robust veterinary infrastructure, like North America and Europe, continue to dominate the Veterinary Vaccines Market share due to their well-established distribution networks and high expenditure on animal healthcare. As emerging economies ramp up their efforts to modernize veterinary services, the global market share is expected to become more evenly distributed, presenting new opportunities for growth and innovation.

Expanding Veterinary Healthcare Infrastructure

Another driver for growth in the veterinary vaccines market is the broadening veterinary healthcare infrastructure in developing nations. In the past, animal health services were relatively underdeveloped in low and middle-income countries. However, recent years have witnessed substantial investments toward improving veterinary facilities, education, and resources. This expanded infrastructure enhances access to routine preventive care like vaccination programs nationally. It also boosts awareness about the importance of vaccinating livestock populations against zoonotic diseases transmissible to humans. Stronger veterinary systems help safeguard public health as well as agricultural development through optimized animal welfare.

Veterinary Vaccines Market Opportunities

Emerging disease outbreaks

The Veterinary Vaccines Market forecast highlights strong global growth driven by rising pet ownership and demand for companion animal vaccines. Technological advances enable tailored immunization, while developing nations expand livestock vaccination programs. Contract manufacturing is on the rise, and emerging disease outbreaks create urgent vaccine needs, favoring companies that can respond swiftly and scale production efficiently.

Market Concentration and Competitive Landscape

To learn more about this report, Download Free Sample

Analyst opinion (Expert Opinion)

The veterinary vaccines sector is at an inflection point where scientific opportunity, commercial concentration, and public-policy priorities intersect.

Leadership remains concentrated among a small set of integrated animal-health groups, but their relative positions are increasingly contestable. Zoetis retains an outsized revenue base compared with peers, underpinning its capacity for large clinical programmes and stockpiling agreements, yet recent analyst commentary and uptake signals point to rising vendor encroachment and margin pressure from rivals (Merck/MSD, Elanco, Boehringer Ingelheim and regional specialists). For context, Zoetis’ animal-health revenues were reported at roughly US$8.5 billion in 2023, and investor commentary in 2025 has highlighted slowing international growth and measurable share-gains for competing portfolios.

The most consequential technical shift is the move toward nucleic-acid and precision antigen platforms (DNA/mRNA) and more sophisticated vectored vaccines that shorten development timelines and permit rapid antigen updates for rapidly evolving pathogens. Conditional and emergency regulatory pathways are already being used for novel veterinary products: the USDA granted conditional clearance for Zoetis’ avian influenza vaccine in 2025, illustrating how regulators will pragmatically deploy conditional licences during outbreaks. This dynamic will reward firms that couple platform IP with scalable manufacturing and cold-chain/logistics capabilities.

Veterinary Vaccines Industry News

• In March 2024, Virbac, an animal health company, announced that it has signed a definitive agreement with ORIX Corporation, a Japan-based diversified financial services organization, to acquire its animal health subsidiary, Sasaeah. Upon completion, this strategic acquisition will provide Virbac a leading position in Japan's farm animal vaccines market, particularly in the cattle segment.
• In December 2023, Indian Immunologicals Limited (IIL), India's market leader in veterinary and human biologicals, announced the construction of a new greenfield veterinary vaccine facility in Hyderabad's Genome Valley to manufacture the Foot and Mouth Disease Vaccine (FMD-Vac) and Foot and Mouth Disease + Haemorrhagic Septicaemia Vaccine (FMD+HS-Vac).
• In November 2023, Merck Animal Health, also known as MSD Animal Health outside of the U.S. and Canada, a division of Merck & Co., Inc., announced that the European Commission has approved BOVILIS CRYPTIUM, the first European Union-licensed vaccine to protect cattle against Cryptosporidium parvum (C. parvum) infection. BOVILIS CRYPTIUM is now licensed in all European Union nations, due to a centralized approval procedure.
• In October 2023, The Pirbright Institute's Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) signed a memorandum of understanding (MOU) with the Vaccine and Infectious Disease Organization of the University of Saskatchewan (USask). The MOU enables greater collaborations and training in vaccine manufacture to foster animal health innovations.

Market Segmentation

•  Animal Type Insights (Revenue, USD BN, 2025 - 2032)
• Companion 
• Equine
• Canine
• Feline
• Livestock 
• Bovine
• Ovine
• Porcine
• Poultry
• Others
•  Technology Insights (Revenue, USD BN, 2025 - 2032)
• Inactivated Vaccines
• Toxoid Vaccines
• Live Attenuated Vaccines
• Subunit and DNA Vaccines
• Recombinant Vaccines
•  Route of Administration Insights (Revenue, USD BN, 2025 - 2032)
• Subcutaneous Injection 
• Intramuscular Injection
• Intranasal Administration
• Others
•  Distribution Channel Insights (Revenue, USD BN, 2025 - 2032)
• Public
• Private
• Regional Insights (Revenue, USD BN, 2025 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Aratana Therapeutics Inc.
• Regeneus Ltd.
• Morphogenesis Inc.
• Karyopharm Therapeutics Inc.
• Zoetis Inc.
• Eli Lilly and Company
• Merck & Co. Inc.
• Boehringer Ingelheim GmbH.
• Elanco Animal Health
• Virbac
• Hester Biosciences Limited
• Ceva Sante Animale
• Phibro Animal Health Corporation
• Kemin Industries, Inc. 
• Finlab 
• Vaxxinova 
• Vira Vaccine Shaya
• VETERQUIMICA SA

Sources

Primary Research Interviews from the following stakeholders

Stakeholders

• Interviews with veterinary vaccine manufacturers, distributors, livestock farmers, poultry farm operators, companion animal clinics, veterinary hospital administrators, and procurement heads across leading global markets.

Specific stakeholders

• R&D directors and product managers at animal health divisions of pharmaceutical companies (e.g., focusing on bovine, swine, poultry, and aquaculture vaccines)
• Veterinarians and clinical practitioners at leading veterinary hospitals and clinics across North America, Europe, and Asia-Pacific
• Livestock and poultry farm operators in regions with intensive animal husbandry (e.g., Brazil, India, China, U.S.)
• Regulatory affairs managers at national veterinary drug authorities (e.g., USDA-APHIS, EMA Veterinary Medicines Division)
• Cold chain logistics and distribution managers handling animal vaccines across emerging markets
• Procurement heads at veterinary chains and networks (e.g., VCA Animal Hospitals, Greencross Vets)
• Feedlot operators and integrated meat producers (e.g., Tyson Foods, JBS, CP Group) leveraging vaccination programs for herd health
• Academia and researchers specializing in immunology and veterinary microbiology

Databases

• Food and Agriculture Organization (FAO) Statistics
• World Organisation for Animal Health (WOAH, formerly OIE) Disease Information Database
• United States Department of Agriculture – Animal and Plant Health Inspection Service (USDA-APHIS)
• European Medicines Agency (EMA) Veterinary Medicines Data
• National Animal Health Monitoring System (NAHMS), U.S.
• Indian Council of Agricultural Research (ICAR) Livestock Data
• Eurostat – Animal Health and Production Statistics
• China Animal Husbandry and Veterinary Yearbook
• World Bank Livestock Sector Reports
• National Bureau of Statistics (China) – Livestock & Poultry Health

Magazines

• Veterinary Practice News
• Poultry World
• The Cattle Site
• Dairy Global
• Pig Progress
• Animal Pharm (Veterinary Health)
• Poultry International
• Aquaculture North America

Journals

• Vaccine (Elsevier, Veterinary Vaccines section)
• Veterinary Microbiology
• Journal of Veterinary Science
• Preventive Veterinary Medicine
• Journal of Dairy Science
• Avian Pathology
• Journal of Swine Health and Production
• Fish & Shellfish Immunology

Newspapers

• The Wall Street Journal – Agribusiness & Animal Health Section
• The Economic Times – Agriculture & Veterinary Segment
• Financial Times – Food and Agribusiness Reports
• The Hindu Business Line – Livestock & Animal Health Coverage
• Nikkei Asia – Agritech & Veterinary Pharmaceuticals
• Reuters – Animal Health & Food Supply Chain Reports

Associations

• World Veterinary Association (WVA)
• American Veterinary Medical Association (AVMA)
• Federation of Veterinarians of Europe (FVE)
• International Poultry Council (IPC)
• International Dairy Federation (IDF)
• Global Aquaculture Alliance (GAA)
• Indian Veterinary Association (IVA)
• Brazilian Association of Animal Protein (ABPA)
• European Federation of Animal Health (AnimalhealthEurope)

Public Domain Sources

• U.S. Food and Drug Administration (FDA) – Center for Veterinary Medicine
• Department of Animal Husbandry & Dairying (Government of India)
• Ministry of Agriculture and Rural Affairs (MARA), China
• European Food Safety Authority (EFSA)
• World Bank – Livestock Sector Innovation Reports
• National Institute of Animal Nutrition and Physiology (NIANP), India
• Australian Pesticides and Veterinary Medicines Authority (APVMA)
• Canadian Food Inspection Agency (CFIA) – Animal Health Reports
• Reserve Bank of India (RBI) Reports – Agriculture & Veterinary Sector Financing

Proprietary Elements

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for last 8 years

*Definition: The veterinary vaccines market involves products such as live attenuated vaccines, inactivated vaccines, recombinant vaccines, and toxoid vaccines that are administered to animals to prevent them from getting infectious diseases. Veterinary vaccines help protect pets and livestock from viral and bacterial diseases and keep animals healthy. Common veterinary vaccines target diseases like rabies, bordetella, leptospirosis, parvovirus, and distemper.